Since expression of the KRAS4AG12V mutant isoform was recently shown to induce metastatic lung adenocarcinomas [230], development of ASOs that specifically target this splice variant could represent an excellent strategy for cancers that rely on mutations in the KRAS oncogene and activation of its downstream pathway, such as the highly aggressive pancreatic ductal adenocarcinoma (PDAC) or lung cancer. The gene discussed is KRAS; the disease is cancer.